Ayodeji Adegunsoye, MD, PhD, MSc, highlights how the underrepresentation of minority populations in pulmonary fibrosis genetic studies hinders accurate disease risk prediction and broader clinical translation.
In an interview with The American Journal of Managed Care® (AJMC®), Ayodeji Adegunsoye, MD, PhD, MSc, FACP, FCCP, assistant professor of medicine at the University of Chicago, explains that many genetic studies of pulmonary fibrosis have excluded minority populations, limiting the generalizability of their findings.
In the first part of this interview, Adegunsoye explained how MUC5B polymorphisms and rare telomere-related gene variants are changing the way clinicians think about pulmonary fibrosis disease progression. Here, he dives into how the lack of representation in research affects the development and usefulness of tools like polygenic risk scores, which may not apply to underserved racial or ethnic groups. According to Adegunsoye, broader inclusion is necessary to ensure genomic tools are equitable and clinically relevant across all affected populations.
This transcript has been lightly edited; captions were auto-generated.
Transcript
Your research focuses on identifying and optimizing treatment for patients with pulmonary fibrosis across racial groups. How has the exclusion of certain populations from genetic studies seemed to impact outcomes thus far?
I think it's a big factor in how we think about the disease itself. So far to date, there have been large exclusions of certain racial populations [and] certain cultural or ethnic populations in many of the genetic studies to date. And that really limits our understanding of what genetics contributes to the disease pathophysiology itself.
These large exclusions of minority populations limit our ability to translate what we find from 1 population to the entire population, so the generalizability becomes incredibly limited. It also impairs our ability to think about polygenic risk scores. Certain pooled genetic risk factors, which we call risk scores, cannot be applied to other populations because they were not derived in them, and so they wouldn't have external values in them.
I think we need to think about making this test more widescale, more broadly implemented, so that the value we get from them are broadly applicable as well.
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen